Aileron Therapeutics Secures $33,000,000 Series E Funding

  • Feed Type
  • Date
    10/29/2014
  • Company Name
    Aileron Therapeutics
  • Mailing Address
    281 Albany St. Cambridge, MA 02139 USA
  • Company Description
    Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeuticsfor the treatment of cancer and other diseases.
  • Website
    http://www.aileronrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $33,000,000
  • Transaction Round
    Series E
  • Proceeds Purposes
    This financing enables Aileron to rapidly move forward the clinical development of ALRN-6924 as well as ongoing translational research.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy